Should You Buy Novavax on the Dip?

NASDAQ: NVAX | Novavax, Inc. News, Ratings, and Charts

NVAX – Leading biotech company Novavax (NVAX) has received temporary approvals for the use of its COVID-19 vaccine from several countries and has filed for emergency use authorization from the U.S. FDA. However, with several high-efficacy vaccines already available in the market, will NVAX be able to successfully commercialize its COVID-19 vaccine candidate? Read more to learn our view.

Novavax, Inc. (NVAX) in Gaithersburg, Md. is a biotechnology company that specializes in developing and commercializing vaccines to fight various respiratory illnesses. Its product pipeline includes its COVID-19 vaccine candidate NVX-CoV2373, nanoparticle influenza vaccine candidate NanoFlu, and respiratory syncytial virus fusion protein nanoparticle candidate ResVAx, etc.

NVAX’s COVID-19 vaccine candidate has received emergency use approvals from several countries so far this year.

However, given the increasing number of fully approved vaccines already available in the market, NVAX’s latest approvals failed to generate a positive reaction from investors. The stock has plummeted 41.7% in price year-to-date and 7.7% over the past five days to close yesterday’s trading session at $83.44.

Click here to checkout our Healthcare Sector Report for 2022

Here is what could shape NVAX’s performance in the near term:

International COVID-19 Vaccine Approval

Several countries are inking purchase agreements with NVAX for its recombinant nanoparticle protein-based COVID-19 vaccine candidate NVX-CoV2373, which is currently undergoing pivotal phase 3 trials. On January 28, NVAX signed a vaccine purchase agreement with the Israeli government. The company will deliver five million doses of the vaccine, with an option to purchase five million additional doses, pending regulatory approval.

Earlier this month, NVAX submitted a request for emergency use authorization of its COVID-19 vaccine with the U.S. FDA. On February 3, NVAX received conditional marketing authorization for its vaccine from the Medicines and Healthcare products Regulatory Agency in Great Britain and provisional vaccine approval from the New Zealand government. And earlier this week, the Singapore Health services authority and Health Canada also approved the NVX-CoV2373 vaccine.

Mixed Financials

For its fiscal third quarter, ended Sept. 30, 2021, NVAX’s total revenues increased 13.9% year-over-year to $178.84 million. This can be attributed to a 127.1% rise in government contract revenues.

However, the company’s total expenses increased 38.5% from the same period last year to $485.99 million. NVAX’s loss from operations worsened 58.4% from the prior-year quarter to $307.14 million. And its net loss widened 63.4% from its year-ago value to $322.43 million, while its loss per share worsened 34.3% year-over-year to $4.31.

Lawsuits

Several law firms have filed class-action lawsuits against NVAX. The lawsuits allege that the company has made false and misleading statements to the market by downplaying the manufacturing problems of its NVX-Cov2373. Furthermore, NVAX allegedly overstated its production capabilities.

POWR Ratings Reflect Uncertainty

NVAX has an overall C rating, which equates to Neutral in our proprietary POWR Ratings system. The POWR Ratings are calculated by considering 118 distinct factors, with each factor weighted to an optimal degree.

NVAX has a C grade for Quality. The company’s trailing-12-month net profit margin is negative 89.31%. However, its levered free cash flow margin is 71.75%, justifying the Quality grade.

Among 449 stocks in the Biotech industry, NVAX is ranked #139.

Beyond what I have stated above, view NVAX ratings for Growth, Momentum, Stability, and Sentiment here.

Bottom Line

NVAX has made solid progress on its COVID-19 vaccine, with multiple international approvals and purchase agreements. However, with several vaccines with more than 90% efficacy already available in the market, investors have remained bearish about the stock despite the company’s latest approvals. Thus, we think investors should wait until NVAX releases its phase-three clinical trial results for its COVID-19 vaccine candidate before investing in the stock.

How Does Novavax, Inc. (NVAX) Stack Up Against its Peers?

While NVAX has a C rating in our proprietary rating system, one might want to consider looking at its industry peers, Vertex Pharmaceuticals Inc. (VRTX), Amgen Inc. (AMGN), Sino Biopharmaceutical Limited (SBHMY), which have an A (Strong Buy) rating.

Click here to checkout our Healthcare Sector Report for 2022


NVAX shares were trading at $84.06 per share on Friday morning, up $0.62 (+0.74%). Year-to-date, NVAX has declined -41.25%, versus a -7.69% rise in the benchmark S&P 500 index during the same period.


About the Author: Aditi Ganguly


Aditi is an experienced content developer and financial writer who is passionate about helping investors understand the do’s and don'ts of investing. She has a keen interest in the stock market and has a fundamental approach when analyzing equities. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
NVAXGet RatingGet RatingGet Rating
VRTXGet RatingGet RatingGet Rating
AMGNGet RatingGet RatingGet Rating
SBHMYGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


Inflation Not Fading Fast Enough for Stock Investors

Investors may have celebrated the end of high inflation too soon. The CPI report shows inflation bouncing higher and thus pushing back the start date for Fed rate cuts. This has the S&P 500 (SPY) coming off recent highs. This begs questions like how much more downside could we see? And when will the bull market get back on track? 44 year investment veteran Steve Reitmeister shares his answers to these questions in this timely commentary including a preview of his top picks to stay ahead of the pack. Read on below for more...

3 Auto Stocks to Consider Over TSLA in April

Tesla (TSLA) reported a decline in deliveries in the first quarter, and Wall Street expects the company to deliver fewer vehicles than last year. Furthermore, rising competition, slowing EV sales, and stretched valuation make TSLA unattractive from an investment standpoint. Considering these factors, investors could consider buying fundamentally strong auto stocks Blue Bird (BLBD), Rolls-Royce Holdings (RYCEY), and Stellantis (STLA) over Tesla (TSLA). Read more...

3 Top-Rated Tech Stock Buys for Value in April

The technology sector is undergoing a notable surge, propelled by increasing digitalization endeavors among businesses and governmental support for technological progress. So, fundamentally sound tech stocks Box Inc. (BOX), Teradata (TDC), and Materialise (MTLS), which seem pretty undervalued, might be ideal buys this month. Continue reading...

Top Software Stocks at the Forefront of Market Gains

The software industry's prospects appear bright due to increasing investments in digital transformation, high demand for advanced software services from various sectors, and the integration of emerging technologies such as generative AI. Therefore, investors could consider buying quality software stocks Autodesk (ADSK), DocuSign (DOCU), and Pegasystems (PEGA) for solid gains. Read more...

Updated 2024 Stock Market Outlook

The bull market continues to rage on with the S&P 500 (SPY) making new highs. That is the past...the question is what does the future hold? That is why 44 year investment veteran Steve Reitmeister provides this updated 2024 Stock Market Outlook to help you carve a path to outperformance the rest of the year. Read on below for the full story...

Read More Stories

More Novavax, Inc. (NVAX) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All NVAX News